Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
6,506.48
(
-1.51%
)
US TECH 100
23,314.40
(
-1.71%
)
Dow Jones
45,577.47
(
-0.96%
)
Brent Oil
108.15
(
3.56%
)
Bitcoin
69,952.99
(
0.08%
)
News Focus
News Focus
Post# of 257263
Next 10
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

genisi

Send PM Follow Ignore
Followers 28
Posts 5148
Boards Moderated 0
Alias Born 05/24/2006

genisi

Re: genisi post# 87045

Monday, 07/26/2010 9:44:04 AM

Monday, July 26, 2010 9:44:04 AM

Post# of 257263
Carfilzomib achieved an ORR of 24% and a median duration of response of 7.4 months in that open label single arm phase IIb trial. Looks good enough for approval.
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

Discover What Traders Are Watching

Explore small cap ideas before they hit the headlines.

Join Today